Charles River Laboratories International (CRL) is a Healthcare company in the Diagnostics Research industry. It has a market capitalization of $16.17B, a trailing price-to-earnings ratio of 32.0 and a free-cash-flow yield of 3.1%. Over the most recent reported fiscal year, revenue declined 0.8% and free cash flow per share grew 7.7%. Nama's AI scorecard rates it Hold, 4.5 out of 10. On 12-month momentum it ranks in the leading band of its market.
AI scorecard
Hold · 4.5/10
The sections balance. As of Nov 7, 2026.
Momentum
Leading · +75.8% over 12 months ex. last
Top 20% of its market on the past year's steady rise.
Shariah screen
Not Shariah Compliant
At least one of the three ratios or the industry test failed.
Off its high
-15.2%
How far the last close sits under the highest price of the past five years.
Market cap
$16.17B
Trailing P/E
32.0
Price / book
5.7
Price / sales
4.1
FCF yield
3.1%
Dividend yield
—
Gross margin
32.7%
Operating margin
11.7%
Net margin
-6.0%
Revenue growth (YoY)
-0.8%
Revenue growth (3-yr annual)
+0.3%
EPS growth (YoY)
-0.4%
FCF/share growth (YoY)
+7.7%
Beta
1.4
Exchange
NYSE
Sector
Healthcare
Industry
Diagnostics Research
CRL earnings
Next report: Feb 17, 2027 (Q4 2026, EPS estimate $3.33).
Beat the EPS estimate in 4 of 4 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q3 2026
Nov 4, 2026
$3.09
$2.97
+4.0%
$982.73M
Q2 2026
Aug 5, 2026
$3.02
$2.74
+10.2%
$1.00B
Q1 2026
May 7, 2026
$2.06
$1.95
+5.6%
$995.83M
Q4 2025
Feb 18, 2026
$2.39
$2.35
+1.7%
$994.23M
CRL analyst price target
Median target $330.00 from 15 analysts, ranging $145.00 – $390.00.
Charles River Laboratories International trades disclosed by members of the US House and Senate under the STOCK Act.
See the full Congress trades board →
Member
Chamber
Trade
Amount
Disclosed
Jefferson Shreve
House
Sell
$15,001 - $50,000
Jun 22, 2025
Jefferson Shreve
House
Buy
$15,001 - $50,000
Jun 22, 2025
Rob Bresnahan
House
Sell
$1,001 - $15,000
May 31, 2025
Rob Bresnahan
House
Buy
$15,001 - $50,000
May 8, 2025
Julie Johnson
House
Buy
$1,001 - $15,000
Feb 12, 2025
Lois Frankel
House
Sell
$1,001 - $15,000
Oct 10, 2023
CRL FAQ
Is CRL a buy?
Nama's AI scorecard currently rates Charles River Laboratories International Hold (4.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is CRL's P/E ratio?
Charles River Laboratories International trades at a trailing price-to-earnings ratio of 32.0.
When does CRL report earnings?
Charles River Laboratories International's next scheduled report is on Feb 17, 2027. Analysts expect EPS of $3.33.
What is the CRL price target?
The median analyst price target from 15 analysts is $330.00, with a range of $145.00 – $390.00.
Is CRL Shariah compliant?
Nama's AAOIFI-style screen reads Charles River Laboratories International as Not Shariah Compliant. At least one of the three ratios or the industry test failed.